TY - JOUR
T1 - Myocardial recovery and the failing heart
T2 - Myth, magic, or molecular target?
AU - Mann, Douglas L.
AU - Barger, Philip M.
AU - Burkhoff, Daniel
N1 - Funding Information:
This research was supported by research funds from the National Institutes of Health (grants RO1 HL58081 , RO1 HL61543 , and RO1 HL-42250 ). Dr. Burkhoff is an employee of CircuLite, Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
PY - 2012/12/18
Y1 - 2012/12/18
N2 - Medical and device therapies that reduce heart failure morbidity and mortality also lead to decreased left ventricular volume and mass and a more normal elliptical shape of the ventricle. These are due to changes in myocyte size, structure, and organization that have been referred to collectively as reverse remodeling. Moreover, there are subsets of patients whose hearts have undergone reverse remodeling either spontaneously or after medical or device therapies and whose clinical course is associated with freedom from future heart failure events. This phenomenon has been referred to as myocardial recovery. Despite the frequent interchangeable use of the terms "myocardial recovery" and "reverse remodeling" to describe the reversal of various aspects of the heart failure phenotype after medical and device therapy, the literature suggests that there are important differences between these 2 phenomena and that myocardial recovery and reverse remodeling are not synonymous. In this review, we discuss the biology of cardiac remodeling, cardiac reverse remodeling, and myocardial recovery with the intent to provide a conceptual framework for understanding myocardial recovery.
AB - Medical and device therapies that reduce heart failure morbidity and mortality also lead to decreased left ventricular volume and mass and a more normal elliptical shape of the ventricle. These are due to changes in myocyte size, structure, and organization that have been referred to collectively as reverse remodeling. Moreover, there are subsets of patients whose hearts have undergone reverse remodeling either spontaneously or after medical or device therapies and whose clinical course is associated with freedom from future heart failure events. This phenomenon has been referred to as myocardial recovery. Despite the frequent interchangeable use of the terms "myocardial recovery" and "reverse remodeling" to describe the reversal of various aspects of the heart failure phenotype after medical and device therapy, the literature suggests that there are important differences between these 2 phenomena and that myocardial recovery and reverse remodeling are not synonymous. In this review, we discuss the biology of cardiac remodeling, cardiac reverse remodeling, and myocardial recovery with the intent to provide a conceptual framework for understanding myocardial recovery.
KW - heart failure
KW - left ventricular remodeling
KW - myocardial recovery
KW - myocardial remission
KW - reverse remodeling
UR - http://www.scopus.com/inward/record.url?scp=84871274086&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2012.06.062
DO - 10.1016/j.jacc.2012.06.062
M3 - Review article
C2 - 23158527
AN - SCOPUS:84871274086
SN - 0735-1097
VL - 60
SP - 2465
EP - 2472
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 24
ER -